You must have the latest - Flash plugin - to view this slideshow. 63-year history of research and clinical excellence
Matthew Meyerson, MD, PhD in the lab 

Nineteen Dana-Farber scientists listed among world's most influential

July 01, 2014

In an affirmation of worldwide respect for the impact of Dana-Farber research, 19 basic scientists and clinical investigators at the Institute have been listed among "the world's most influential scientific minds." The ranking was based on how frequently their research discoveries have been cited by peers in the past decade.

Antibody halts cancer-related wasting condition

July 13, 2014

Dana-Farber scientists identify a protein that is a cause of cachexia, a severe wasting of fat and muscle in half of all cancer patients, and show that blocking the protein in mice can prevent or halt the debilitating condition.

Study identifies novel genomic changes in the most common type of lung cancer
July 09, 2014

Dana-Farber and colleagues from the Cancer Genome Atlas (TCGA) Research Network identified novel mutations in a well-known cancer-causing pathway in lung adenocarcinoma, potentially identifying a greater number of patients with treatable mutations because many potent cancer drugs that target these mutations already exist. Additionally, these findings may expand the number of possible new therapeutic targets for this disease.

Signal from fat tissues improves insulin secretion in diabetic mice, suggests potential therapy
July 03, 2014

Research led by Bruce Spiegelman, PhD, and colleagues shows that adipsin, a cell signaling protein made by fat cells, plays a critical, previously unsuspected role in stimulating insulin secretion to control blood sugar, and the discovery could have implications for treatment of type 2 diabetes.

Dana-Farber acquires Commonwealth Hematology-Oncology
July 01, 2014

Dana-Farber Cancer Institute is acquiring the Commonwealth Hematology-Oncology (CHO) physician practice and extending its sophisticated cancer care model further into the community, effective July 1, 2014.

ASCO Clinical Practice Guideline: Disease Management in Advanced HER2-Positive Breast Cancer With Brain Metastases (ASCO Post)

July 10, 2014

Dr. Eric P. Winer co-chaired an expert panel that developed a clinical practice guideline on disease management for patients with advanced HER2-positive breast cancer and brain metastases.

Ado-Trastuzumab Emtansine Improves Progression-Free Survival vs Physician’s Choice in Advanced HER2-Positive Breast Cancer (ASCO Post)
July 10, 2014

Dr. Ian E. Krop led a study showing that the anti-body drug ado-trastuzumab emtansine significantly prolonged progression-free survival in patients with progressive HER2-positive advanced breast cancer.

Scientists publish a deep look at DNA mutations in lung cancer (Boston Globe)
July 10, 2014

Dr. Matthew Meyerson led a genomic study of lung cancer which has provided information that could help scientists devise new treatments.

Prostate Cancer Outcomes May Improve Under Affordable Care Act (Renal & Urology News)
July 07, 2014

Dr. Paul L. Nguyen led a study showing prostate cancer patients with health insurance are less likely to have metastatic disease or die from the cancer than those without health insurance.

JPMorgan's Dimon has throat cancer, to begin treatment shortly (Reuters)
July 02, 2014

Dr. Robert Haddad commented on JPMorgan Chase CEO Jamie Dimon being diagnosed with throat cancer.

FDA Panel Puts Brakes on Anti-PARP Drug (MedPageToday)
June 27, 2014

Dr. Joyce Liu commented on the Oncologic Drugs Advisory Committee vote to delay approval of the PARP inhibitor olaparib.

Johnson & Johnson Innovation Center to fund $10 million Janssen Biotech, Dana-Farber partnership (Boston Business Journal)
June 24, 2014

Johnson & Johnson Innovation Center will fund a $10 million partnership with Dana-Farber and Janssen Biotech to work on lung cancer immunotherapy drugs.

Breast Cancer Support Group-Milford(3)

July 13, 2014

4:30 PM - 5:30 PM

20 Prospect Street, 2nd Floor

An opportunity for women who would like to meet with others to explore ways to cope with their diagnosis and its effect on their lives through education and support.

Call Ann Sullivan at 508-488-3783 to register.

This program is free and refreshments will be provided.


Caring for the Caregiver-Milford(3)

July 13, 2014

6:00 PM - 7:00 PM

20 Prospect Street, 2nd Floor

This is a support group for those who have a loved one or friend with cancer. The program will provide practical information to support you in your role as a caregiver, as well as offer an opportunity to meet and gain support from others coping with similar issues.

Call Ann Sullivan, LICSW at 508-488-3783 to register.


Sarcoma Support Group(2)

July 14, 2014

12:30 PM - 1:30 PM

Smith Building, Room 330

This group is an opportunity to share information, coping skills and network with other Sarcoma patients and their caregivers.

*A dial in option is available if you are unable to attend this group in person.
Registration is required.  Please call Larissa Hewitt at 617-582-7548

  • Patient referral information, clinical resources and more.

  • Make an Appointment

    For adults:

    For children:

    Or complete the online form.

  • Clinical Trials

    Search current cancer clinical trials at Dana-Farber.

  • How to Help

    Yawkey Center for Cancer Care entrance 

    There are many ways to support Dana-Farber and the Jimmy Fund.

    give now button
  • Dana-Farber Blog

    Insight Blog screenshot 

    Insight features the latest in cancer care and research news from Dana-Farber.
    Read the blog

  • Dana-Farber eNewsletter

    Dana-Farber Spotlight 

    Stay current on the latest news by signing up for Spotlight, our email newsletter.
    View current issue
    Subscribe now